Publikasi Scopus FKUI Terkait Covid-19 Update 13 Desember 2021

Subali A.D., Wiyono L., Yusuf M., Zaky M.F.A.
57222071247;57207889054;57225124812;57360030000;
The potential of volatile organic compounds-based breath analysis for COVID-19 screening: a systematic review & meta-analysis.
2022
Diagnostic Microbiology and Infectious Disease
102
2
115589
2
Faculty of Medicine, Universitas Brawijaya, East Java, Indonesia; Faculty of Medicine, Universitas IndonesiaJakarta, Indonesia
Subali, A.D., Faculty of Medicine, Universitas Brawijaya, East Java, Indonesia; Wiyono, L., Faculty of Medicine, Universitas IndonesiaJakarta, Indonesia; Yusuf, M., Faculty of Medicine, Universitas Brawijaya, East Java, Indonesia; Zaky, M.F.A., Faculty of Medicine, Universitas Brawijaya, East Java, Indonesia
COVID-19 is a major problem with an increasing incidence and mortality. The discovery of Volatile Organic Compounds (VOCs) based on breath analysis offers a reliable, rapid, and affordable screening method. This study examined VOC-based breath analysis diagnostic performance for SARS-COV-2 infection compared to RT-PCR. A systematic review was conducted in 8 scientific databases based on the PRISMA guideline. Original English studies evaluating human breaths for COVID-19 screening and mentioning sensitivity and specificity value compared to RT-PCR were included. Six studies were included with a total of 4093 samples from various settings. VOCs-based breath analysis had the cumulative sensitivity of 98.2% (97.5% CI 93.1%−99.6%) and specificity of 74.3% (97.5% CI 66.4%−80.9%). Subgroup analysis on chemical analysis (GC-MS) and pattern recognition (eNose) revealed higher sensitivity in the eNose group. VOC-based breath analysis shows high sensitivity and promising specificity for COVID-19 public screening. © 2021 Elsevier Inc.
breath analysis, breath-testing; COVID-19, screening, diagnosis, volatile organic compound
volatile organic compound; volatile organic compound; breath analysis; chemical analysis; coronavirus disease 2019; demography; diagnostic value; human; intermethod comparison; mass fragmentography; meta analysis; nonhuman; outcome assessment; pattern recognition; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; real time polymerase chain reaction; Review; risk assessment; screening test; sensitivity and specificity; systematic review; breath analysis; diagnosis; electronic nose; isolation and purification; mass fragmentography; mass screening; procedures; Breath Tests; COVID-19; Electronic Nose; Gas Chromatography-Mass Spectrometry; Humans; Mass Screening; SARS-CoV-2; Sensitivity and Specificity; Volatile Organic Compounds
Elsevier Inc.
7328893
34879323
Review
Q1
1027
4216